Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Sanyal and colleagues reported the MASLD Phase 2a in Nature Medicine documenting hepatic steatosis reduction (PMID 38858523)
This raises the possibility of GLP-1/GIP/glucagon receptor triagonist becoming a new treatment for the reversal of liver fibrosis in MASH
The primary end point of interest was the change in urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) from the time of initiation of the GLP-1 RA to discontinuation or final follow-up
Therapeutic advances in gastroenterology
Seguici sui nostri social Iscriviti alla newsletter DIAMOND SPONSOR PLATINUM SPONSORS GOLD SPONSORS SILVER SPONSORS
This overview explores how well Eden delivers on those factors and whether its approach makes sense when comparing quality and price
US$ 27.81
US$ 29.40
US$ 29.95
US$ 25.20
